Sonoma PharmaceuticalsSNOA
13F holders, Q4 2024 (December 31)9holders −5
0new positions
5sold out
$2.69avg. 13F price*
At the end of Q4 2024, 9 institutions reported holding Sonoma Pharmaceuticals Inc. (SNOA) in their 13F filings, down 5 from Q3 2024. 0 opened new positions and 5 sold out. The largest holders were UBS Group AG ($47K), Tower Research Capital LLC (TRC) ($6K) and JPMorgan Chase & Co. ($371).
- Company
- Sonoma Pharmaceuticals Inc.
- CUSIP
- 83558L303
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 5 | $33K |
All 13F filers, Q3 2024 → Q4 2024: 4,709 shares bought and 12,368 shares sold, net −7,659 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| UBS Group AG | 0.00% | Add +36.9% | 17,430 | $47K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -41.9% | 2,407 | $6K |
| JPMorgan Chase & Co. | 0.00% | No change | 138 | $371 |
| BlackRock, Inc. | 0.00% | No change | 113 | $304 |
| US Bancorp \de | 0.00% | No change | 25 | $67 |
| Bank of America Corp. | 0.00% | Add +300.0% | 12 | $32 |
| Morgan Stanley | 0.00% | No change | 4 | $11 |
| Allworth Financial LP | 0.00% | No change | 3 | $8 |
| Danske Bank A/S | 0.00% | No change | 1 | $3 |
"% of holder's portfolio" is SNOA's weight in each manager's 13F, not the share of Sonoma Pharmaceuticals Inc. the manager owns.